V T Ferrero1, M M Oset2, J P Masferrer3, E H Pardo4, E J Sorolla5, S C Largo6. 1. Department of Radiation Oncology, Hospital Universitary de Sant Joan D'Alacant, Carretera Nacional 332 Alicante-Valencia s/n, Sant Joan D'Alacant, 03550, Alicante, Spain. doctor.vicente.tormo@gmail.com. 2. Department of Radiation Oncology, Hospital Universitary de Sant Joan D'Alacant, Carretera Nacional 332 Alicante-Valencia s/n, Sant Joan D'Alacant, 03550, Alicante, Spain. 3. Department of Radiation Oncology, Hospital Universitari Son Espases, Palma de Mallorca, Spain. 4. Department of Radiation Oncology, Hospital Universitario de Araba, Vitoria, Spain. 5. Department of Radiotherapy, Hospital Clínico Universitario de Valencia, Valencia, Spain. 6. Department of Radiation Oncology, Hospital Clínico San Carlos, Madrid, Spain.
Abstract
PURPOSE: Radiotherapy-induced dysfunction of the gastrointestinal tract is common in cancer patients and has a significant impact on their quality of life. In this study, we investigated the prevalence of breakthrough cancer pain (BTcP) in patients undergoing 3D pelvic radiotherapy and who had proctalgia. METHODS: This observational, multicenter, cross-sectional epidemiological study was performed in 13 Spanish hospitals. Data were obtained on the presence and characteristics of BTcP, demographics, common comorbidities, and treatments prescribed to the patients. RESULTS: The prevalence of BTcP in patients undergoing pelvic 3D external radiotherapy with proctalgia (N = 105) was 48.6% (95% CI 39.0-58.1%). BTcP was further characterized in 59 patients. The mean (± SD) intensity of the BTcP episodes was 7.45 ± 1.47 in a visual analog scale. We found several statistically significant associations between the descriptive variables of BTcP with demographic and clinical variables associated with the tumor or the patient, such as an increased number of BTcP episodes per day depending on the presence or absence of diabetes (p = 0.001, Chi-square) or time to the onset of pain relief depending on the location of the tumor (p = 0.019, Chi-square). Fentanyl was the drug of choice in BTcP episodes for 95% of the patients. CONCLUSIONS: This study demonstrated a high prevalence of BTcP prevalence in cancer patients undergoing pelvic 3D radiotherapy and with proctalgia. Although the variables determining the onset of BTcP are still unclear, our results could help in the design of future clinical studies addressing the treatment of BTcP in these patients.
PURPOSE: Radiotherapy-induced dysfunction of the gastrointestinal tract is common in cancerpatients and has a significant impact on their quality of life. In this study, we investigated the prevalence of breakthrough cancer pain (BTcP) in patients undergoing 3D pelvic radiotherapy and who had proctalgia. METHODS: This observational, multicenter, cross-sectional epidemiological study was performed in 13 Spanish hospitals. Data were obtained on the presence and characteristics of BTcP, demographics, common comorbidities, and treatments prescribed to the patients. RESULTS: The prevalence of BTcP in patients undergoing pelvic 3D external radiotherapy with proctalgia (N = 105) was 48.6% (95% CI 39.0-58.1%). BTcP was further characterized in 59 patients. The mean (± SD) intensity of the BTcP episodes was 7.45 ± 1.47 in a visual analog scale. We found several statistically significant associations between the descriptive variables of BTcP with demographic and clinical variables associated with the tumor or the patient, such as an increased number of BTcP episodes per day depending on the presence or absence of diabetes (p = 0.001, Chi-square) or time to the onset of pain relief depending on the location of the tumor (p = 0.019, Chi-square). Fentanyl was the drug of choice in BTcP episodes for 95% of the patients. CONCLUSIONS: This study demonstrated a high prevalence of BTcP prevalence in cancerpatients undergoing pelvic 3D radiotherapy and with proctalgia. Although the variables determining the onset of BTcP are still unclear, our results could help in the design of future clinical studies addressing the treatment of BTcP in these patients.
Entities:
Keywords:
Breakthrough pain; Pelvic 3D radiotherapy; Proctalgia
Authors: T Jonathan Yang; Jung Hun Oh; Christina H Son; Aditya Apte; Joseph O Deasy; Abraham Wu; Karyn A Goodman Journal: Gastrointest Cancer Res Date: 2013-09
Authors: Marieke H J van den Beuken-van Everdingen; Laura M J Hochstenbach; Elbert A J Joosten; Vivianne C G Tjan-Heijnen; Daisy J A Janssen Journal: J Pain Symptom Manage Date: 2016-04-23 Impact factor: 3.612
Authors: Francisco Villegas; Verónica Martínez-Borba; Carlos Suso-Ribera; Diana Castilla; Irene Zaragoza; Azucena García-Palacios; Carlos Ferrer Journal: Int J Environ Res Public Health Date: 2021-06-03 Impact factor: 4.614